axatilimab
axatilimab: sourced relationships with 1 company · 22 clinical trials tracked.
axatilimab evidence translation
What we can confirm
22 tracked trials
What it means
What to watch
Prepared research question
How could axatilimab → SNDX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Syndax Pharmaceuticals Inc (SNDX) Chronic Graft-versus-host-disease; Idiopathic Pulmonary Fibr… | Phase 2 |
Clinical Trial Registry Records (22)showing 10 most recent
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
Primary endpoint: Phase 2 Dose Level determination
IIT2024-02-SHIAO-ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Primary endpoint: Overall Response Rate (ORR)
A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Primary endpoint: Objective Response (OR) at 6 months
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Primary endpoint: Safety and Adverse Events (AEs)
Axatilimab for Sclerotic Chronic Graft-Versus-Host Disease
Primary endpoint: Overall response rate (ORR) in sclerotic manifestations
A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After Systemic Therapy
Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs)
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
Primary endpoint: Objective Response (OR) at 6 months
A Phase II b Study of Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
Primary endpoint: Best Overall Response Rate (ORR)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
Primary endpoint: Event Free Survival (EFS)
Frequently asked questions
Which companies have sourced relationships with axatilimab?
axatilimab has dated SEC/FDA relationship records for Syndax Pharmaceuticals Inc.
How many clinical trials involve axatilimab?
BioSniper tracks 22 clinical trials involving axatilimab.